Topics:

Breast Cancer

Breast Cancer

Loss of the tumor suppressor PTEN was found to be a frequent mechanism of resistance to treatment with the PI3K-alpha inhibitor BYL719 in women with breast cancer.

Two early trials studying CDK inhibitors in metastatic breast cancer have shown impressive activity in HR-positive disease, according to data presented at the AACR annual meeting.

A phase I study of intermittent oral lapatinib in patients with HER2-amplified breast cancer escalated up to 7,000 mg per day (shown to be effective in mouse models), found that plasma concentrations of the drug did not increase proportionately with the oral dose, impeding clinical translation of this method.

After a 30-year follow-up, it was shown that women treated with fertility drugs did not have an increased risk of breast cancer compared with women not exposed to the treatments.

Older age and comorbidities were associated with a higher risk of failing to complete trastuzumab therapy in a new study of older women with early-stage breast cancer, where nearly 20% failed to complete the treatment.

New guidelines supporting the broader use of sentinel lymph node biopsy in women with early-stage breast cancer have been issued by ASCO.

New reviews look at the promise of a new blockbuster drug for cancer, as well as its drawbacks.

Pages

Subscribe to
Please Wait 20 seconds or click here to close